Not sure if it was an oversight or misinterpretation, but ARX-04 is not up for being a prescription out of the hospital. I question how many times it would be dispensed in the hospital setting. Don't get me wrong, I think there is big potential and a lot of revenue to tap into, but the numbers, I believe, are skewed as many would not need opiods and for those who do, maybe one dose would be given?
Reading the latest report that the initial IV costs $145 or so, what is it in comparison to 04? Obviously the administering of the drug is near $0, but wondered what we are comparing price wise and what kind of savings the company is suggesting a hospital can save?
Though the number of patients is drastically lower, I believe the revenue for an UC drug that works well is pretty high. I thought the projected revenue for Uceris, bought by Salix from Santarus, was/is projected to top $1 billion annually in revenue.
If you are looking for a buyout, it would seem the best strategy for maximizing the price of the company would be to shoot for a positive phase II trial in UC with Dolcanatide instead of a phase III for OIC. Seems to me with two indications of IBS and CIC, the drug would be prescribed off label anyways.